Matrix metalloproteinases and their inhibitors

Anticancer Research

Volumn 19, Issue 2 C, 1999, Pages 1589-1592

  Kugler, A ^a  

^a NONE

Author keywords

Matrix metalloproteinases; Renal cell carcinoma; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

COLLAGENASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CONFERENCE PAPER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; ZYMOGRAPHY;

CARCINOMA, RENAL CELL; COLLAGENASES; DISEASE PROGRESSION; GELATINASES; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0033061405     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Baker AH, Zaltsman AB, George SJ, Newby A C: Divergent effects of tissue inhibitor of metalloproteinase -1,-2,-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro.J. Clin. Invest 101: 1478-1487, 1998.
2. Denton RM, Tavare JM:Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against.. Eur. J. Biochem. 227: 597-611, 1995.
3. Garbisa S, Scagliotti G, Masiero L, Francesco CD, Caenazzo C, Onisto M: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548-4549, 1992.
4. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65: 209-213, 1996.
5. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nikajima M: Evaluation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurence in patients with urothelial carcinoma. Cancer 78: 2379-2387, 1996.
6. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson J.B, Williams JL, Rees RC: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177-182, 1994.
7. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa: Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci 107: 2373-2379, A 1994.
8. He C, Wilhelm SM, Pentland AP, Marmer B L. Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci 86: 2632-2636, 1989.
9. Hewitt R, Bennet T, Stetler-Stevenson WG:Invasion of SW 480 cells is influenced by rTIMP-1 and rTIMP-2Am. J Pathol in press, 1998.
10. Jonat C, Rahmsdorf HJ, Park KK, Andrew CB, Gebel St, Ponta H, Herrlich P: Antitumor promotion and antiinflamation: down-modulation of AP-1 (fos/jun) activity by glucocorticoid hormone. Cell 62: 1189-1204, 1990.
11. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert R-H: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol in press, 1998.
12. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of matrix metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493-4498, 1993.
13. Manicourt DH, Fujimoto N, Obata K, Thonar E JM: Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinase 1 in patients with rheumatoid arthritis.Arthritis and Rheumatism 38: 1031-1039, 1995.
14. Milani S, Herbst H, Schuppan D, Grappone C, Pelligrini G, Pinzani M, Casini A, Calabro A, Ciancio G, Stefanini F, Burroughs AK, Surrenti C: Differential expression of matrix-metalloproteinase-1 and-2 Genes in normal and fibrotic liver.Am J Pathol 144: 528-537, 1994.
15. Nemeth JA, Rafe A, Steiner M, Goolsby CL: TIMP-2 growth-stimulaory activity: a concentration-and cell type-specific response in the presence of insulin. Exp Cell Res 224: 110-5, 1996.
16. Nuovo G J, MacConnell PB, Simsir A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinomas. Cancer Res 55: 267-265, 1995.
17. Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat. A matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg. Oncol 23: 526-531, 1997.
18. Ries C, Kolb H, Petrides PE: Regulation of 92-kDa gelatinase release in HL-60 leukemia cells: tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion. Blood 83: 3638-3646, 1994.
19. Shima I, Sasaguri Y, Nakano R, Yamana H. Fujita H, Kakegawa T, Morimatsu M: Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br J Cancer 67: 721-727, 1993.
20. Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinoma correlates with tumor recurrence. Int J Cancer 59: 339-344, 1994.
21. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt Th.J., Drouin J, Karin M: Transcriptional Interference between c-jun and the glucocorticoid receptor: mutual inhibition of DNA binding to direct protein-protein interaction. Cell 62: 1205-1215, 1990.